



# Governor Raimondo's Task Force on Overdose Prevention and Intervention

December, 2020

**DIRECTOR NICOLE ALEXANDER-SCOTT, M.D., M.P.H.;** RHODE ISLAND DEPARTMENT OF HEALTH

**DIRECTOR KATHRYN POWER, M.Ed.;** RHODE ISLAND DEPARTMENT OF BEHAVIORAL HEALTHCARE,  
DEVELOPMENTAL DISABILITIES, AND HOSPITALS



# WELCOME & ANNOUNCEMENTS



# Recovery Friendly Workplace December Designees



The Recovery Friendly Workplace Initiative gives business owners and managers the resources and support they need to foster a supportive environment that encourages the success of their employees in recovery. Learn more at [www.recoveryfriendlyRI.com](http://www.recoveryfriendlyRI.com).



# Addiction + Overdose Evidence Update

---

Presentation to Governor's Overdose Task Force

December 9, 2020


RHODE  
ISLAND


# Performance trends are generally strong or stable, but deaths are historically high.

Pillar	Metric	Trend, 2019-2020
Prev	New opioid prescriptions	Downward
Prev	Benzo + Opioid Combo Rx	Downward
Prev	Opioid Rx to <18-year olds	Downward
Prev	Project SUCCESS classes	Upward
Resc	Naloxone distributed	Upward
Resc	Naloxone to high-risk groups	Upward
Resc	Naloxone covered by insurance	Stable
Resc	Overdoses - layperson gave naloxone	Stable
Tx	People in sustained medication assisted treatment	Stable*
Tx	People in medication assisted treatment	Stable*
Tx	People in medication assisted treatment, % BIPOC	Stable*
Tx	ED visits for those with MAT record	Downward
Tx	Treatment within 6 months of first OUD Dx or OD	Downward
Rec	Recovery Center enrollment, current and new	Upward
Rec	Licensed Peer Recovery Coaches	Upward
Rec	Wages > FPL for those with a prior OUD diagnosis	Downward
Rec	Recovery – self-reported well-being	Upward

\* Treatment enrollment is plateauing across all groups in 2020 after several years of steady climbing

### Cumulative Overdose Deaths, 2014-2020





Rhode Island may exceed **400 overdose fatalities** this year, 25% higher than our highest year, despite:

- ✓ Three years of falling death rates,
- ✓ Heroic efforts to continue services during COVID, and
- ✓ Stable, strong performance metrics across all pillars.

What changed?  
How do we know?  
How do we respond?

# First Step: Addiction + Overdose Evidence Update

The Task Force Co-Chairs charged EOHHS with learning as much as possible about the shape, drivers, and trajectory of the current crisis – and recommending strategic actions.

## Qualitative Analysis (Key informant interviews)

The team spoke to over 100 people in 44 Key Informant Interviews or Focus Groups - a diverse group of community agency and state agency staff, and providers, as well as people who use drugs and family members of people who use drugs. Topics included:

1. What works well in Rhode Island (strengths of our response)
2. Changes that may have led to rising deaths – both before and because of COVID
3. The impact of structural racism on deaths
4. Strengths and weaknesses of the statewide response structure
5. What “magic wand” changes would make the biggest difference?

## Quantitative Analysis

Analyzed demographic, medical, and economic differences in two cohorts of people:


- (1) 2020 cohort: those who died between Dec. 2019 and June 2020 and
- (2) 2019 cohort: those who died between Dec. 2018 and June 2019

We also looked at **environmental factors** – corrections census, Roger Williams Medical Center outpatient addiction program closure - that may have affected outcomes

# Overdoses grew by 23% in the study period, but the groups were largely demographically similar, overall

There were few difference between the two groups – but as we’ll see in coming slides, those differences were critical and often visible only in more refined cuts of the data.

Factor	% of total 2019	% of total 2020	% of total, Diff.
Medicaid	60%	58%	-2%
Female	30%	27%	-3%
Veteran	6%	8%	+2%
Race: White	78.5%	79.0%	+0.5%
Race: African American	8.3%	6.3%	-2.0%
Race: Asian, Native American, Mixed, Other, Unk	13.2%	14.7%	+1.5%
Ethnicity: Hispanic	5.5%	9.0%	+4.5%
Ages: 20-29	14.4%	13.8%	-0.6%
Ages: 30-39	24.9%	26.8%	+1.9%
Ages: 40-49	26.0%	24.0%	-2.0%
Ages: 50-59	23.2%	25.5%	+2.3%
Ages: 60-69	9.9%	8.9%	-1.0%
Ages: 70+	1.1%	0.9%	-0.2%
UI, TDI, PUA in 3 months prior to death			





# Analytics: Comparing those who died in 2020 to 2019

Population	2019	2020
Full Population	181	223
<i>Also in Medicaid</i>	108	129
Medicaid % of Total	60%	58%

## Also during this period:

- Take home methadone started March 2020
- The Department of Corrections census fell by almost 30%
  - 425 more releases than admissions in March and April to allow for extra capacity
  - Fewer arrests as proactive policing and criminal activity fell
  - Number of people in Medication Assisted Treatment (MAT) fell proportionally
- Roger Williams Medical Center closed for MAT – but did not affect death rates
- No reported decrease in drug supply or market activity due to travel restrictions

# The significant differences – though few – when combined contributed to a substantial rise in overdoses

Prior anxiety and methadone (treatment and as a contributing cause of death) – especially for 50-59 year olds

			Factor	% of pop 2019	% of pop 2020	% of pop, Diff.	Change in ppl, 2019 to 2020	P-value
<i>Total population</i>	<b>2019</b>	<b>2020</b>	Full Population: Fentanyl-involved death	69.6%	74.0%	+4.4%	+29	0.17
Vitals	181	223	Medicaid (MCD) population: Prior Anxiety diagnosis	44.4%	52.7%	+8.3%	+20	0.10
Medicaid	108	129	Methadone listed as cause of death + methadone treatment within 3 mo of death and in MCD	50% (6 of 12)	69% (18 of 26)	+19%	+12	
Medicaid % of Total	60%	58%						
<i>50-59 year olds</i>	<b>2019</b>	<b>2020</b>	50-59 years: Methadone contributed to death	0.9%	5.4%	+4.5%	+6	0.00
Vitals	42	57	50-59 years (MCD): Prior Anxiety	9.3%	19.4%	+10.1%	+15	0.00
Medicaid	27	41	50-59 years (MCD): Methadone tx within 3 mo of death	0.9%	7.8%	+6.9%	+9	0.00
Medicaid % of Total	64%	72%	50-59 years (MCD): Prior Alcohol Use Disorder	7.4%	15.5%	+8.1%	+12	0.02
			50-59 years (MCD): Prior SUD (excluding OUD) Dx	16.7%	24.8%	+8.1%	+13	0.40
<i>Location of Death</i>	<b>2019</b>	<b>2020</b>	Died at home: Married	7.5%	21.1%	+13.6%	+17	0.00
Died Elsewhere	101	114	Died at home: Any Medicaid claim	62.5%	50.5%	-12.0%	+5	0.05
Medicaid	58	74	Died at home: Tobacco listed as a contr. cause of death	58.8%	46.8%	-12.0%	+4	0.05
Died at Home	80	109	Died elsewhere (MCD): Prior OUD diagnosis	48.3%	62.2%	+13.9%	+18	0.05
Medicaid	50	55	Died elsewhere (MCD): Prior AUD diagnosis	55.2%	40.5%	-14.6%	-2	0.05
Medicaid % of Home	62.5%	50.5%						

Also, heroin dropped to nearly zero

Note that methadone is rarely the *only* drug that contributed to death

Both methadone factors are also significant for 30-39 year olds

In 2020, those who died elsewhere were also 3x more likely to have a prior overdose (23% vs. 7%)


51% (+28) more men died at home than in 2019, but the difference was not significant

# Despite saturating the market, fentanyl-involved deaths are still growing – as are deaths with combined drugs and methadone

“2020”: Dec. 2019 – June 2020

“2019”: Dec. 2018 – June 2019

Drug Type Noted on Death Certificate at Time of Death



# In summary, our data show evidence of various states of recovery, pre-existing BH diagnoses, and continued fentanyl contamination.

*Text in tan relate to Medicaid-specific findings*

The 2020 cohort has more evidence of recovery, though possibly fragile...	...more likely to have a BH diagnosis	... and more likely to die from fentanyl, methadone or other substances
<ul style="list-style-type: none"> <li>• More likely to have <b>died before rescue arrived</b> (+36%, +51% for men)</li> <li>• <b>More people had wages, but median wages were lower</b> in six months prior to death (+25ppl w/ wages &gt; \$0; -\$1,200 in median wages)</li> <li>• More likely to have <b>recent unemployment insurance</b> (4x growth in # with UI/PUA in 3 mos. prior to death; 60 fewer days between payment and death)</li> <li>• <b>Methadone treatment within 3 months prior to death</b> (+12 ppl, +20% of all people with methadone at time of death)</li> <li>• <b>Longer time since last overdose</b> (+ 80 days)</li> </ul>	<p>BH diagnoses of note include:</p> <ul style="list-style-type: none"> <li>• <b>Anxiety</b> (+20,+8.27%; +15, +10.1% of 50-59yo)</li> <li>• <b>Depression</b> (+14, +3.3%; +12, +7.6% of 50-59yo)</li> <li>• <b>Alcohol Use Disorder for 50-59 population</b> (+12, +8% of 50-59yo)</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Fentanyl</b> (+39, +4.5%)</li> <li>• <b>Methadone</b> that contributes to death (+23, +4.%) <ul style="list-style-type: none"> <li>• 75%, up from 68% in 2019, have methadone in “Cause Line A” – the primary cause of death, but almost always with other substances. Methadone alone as a cause of death is rare and has not significantly varied since 2014.</li> </ul> </li> <li>• <b>“Combined”</b> (+23, +4.5%)</li> <li>• <b>Tobacco</b> that contributes to death (+16, +5.7%)</li> </ul>

# What we learned – Qualitative Research

Here are some of the most compelling lessons from the qualitative research:

## Harm Reduction:

- Deadly Fentanyl, found in substances beyond just opioids, demands an urgent focus on broad, in-depth, and culturally competent Harm Reduction services, including face to face services and more help to people leaving prison
- Messaging should be direct and specific and should also educate people on what an overdose looks and feels like
- Rhode Island should find ways to separate services for people who use drugs from the criminal justice system

## Recovery:

- Rhode Island should continue to prioritize investments in Peer Recovery Specialists - and ensure that we recruit more Peer Recovery Specialists of color, to create more culturally competent services
- We must also do better to address the social determinants of health that help shore up people's recovery systems – affordable housing, stable employment, etc. - to help keep people in recovery and address racial disparities in care
- We should consider new ways of measuring recovery, to reflect more than just participation in MAT

## Governance:

- There are gaps in the ways that we track the work that we do, carry out project management, and create lines of accountability, and include true community voice, especially from community members of color and people who use drugs
- Creating a stronger governance structure would allow the state as a whole to address the rising number of deaths

# What we learned – Qualitative Research

Here are some of the most compelling lessons from the qualitative research:

## Treatment:

- Rhode Island gets a lot right with our treatment services, including MAT, especially for people with insurance
- However, there are still barriers to treatment for all substances, including alcohol, that we must address
- It is always critical to raise the quality of treatment, through a more responsive continuous quality improvement and feedback system – and by increasing the number of providers of color for more culturally competent care

## Prevention:

- We must look far upstream for true prevention, addressing social determinants, violence and trauma, and disparities and discrimination
- We need proven prevention strategies for people who do not use drugs or alcohol, those in recovery, and across the lifespan – including strategies for older users.
- The key to prevention is similar to what it takes to build recovery capital, including social determinants of health

## Messaging:

- There are challenges in our current message – content, messengers, and audience
- We need an ongoing in-depth discussion about the most effective messaging and messengers throughout the pillars, with a focus on culturally and linguistically appropriate language and support for real-time critical communication needs

# Findings: Response Challenges + Drivers of Fatal Overdoses

## Drivers of Fatal Overdoses Identified in Quantitative and Qualitative studies

The 2020 group showed more evidence of being in a fragile state of recovery before death and were more likely to die at home before rescue arrived. They may have overdosed due to:

- A. Sustained presence of **fentanyl and analogues** in the drug supply (present in many types drugs, and potentially growing in potency)
- B. **COVID-driven** social isolation, fear of disease, and economic insecurity
- C. These factors are more acute for communities of color, for whom **historical inequities and ongoing structural racism** have deprived them of equitable capital (recovery, financial, social), trust in institutions, and access to equitable services.

## Response Challenge Identified in Qualitative Study

D. An insufficient governance and project management structure limits our ability to guide a consistent, focused, strategic response that weaves emerging information into action.

# Core Recommendation from Evidence Update

---

Accelerate a  
**tightly-coordinated, more inclusive strategy**  
centered on  
**harm reduction and recovery resiliency**  
for people at high risk of fatal overdose right now  
**to save lives.**



# Existing Work to Address the Drivers of Rising Deaths

Here are examples of recent Community and State activities most focused on addressing rising overdose deaths:

Pillar	Projects
Harm Reduction	<ol style="list-style-type: none"> <li>1. Through the CARES Act dollars, funded:               <ol style="list-style-type: none"> <li>a) 10,000 Chances Project: Purchase and distribution of 10,000 naloxone kits in December</li> <li>b) New funding for Peer Outreach Team, who have been working and distributing harm reduction kits, adapting quickly to continue throughout COVID</li> <li>c) New van for AIDS Care Ocean State for clean needle distribution</li> <li>d) Reworking naloxone messaging short-term (for December)</li> </ol> </li> <li>2. Naloxone access through pharmacies and law enforcement agencies carrying kits</li> </ol>
Recovery	<ol style="list-style-type: none"> <li>1. More Peer Recovery Specialists positions filled – and now being reimbursed by insurance</li> <li>2. Recovery Friendly Workplace program</li> <li>3. More COVID and SOR dollars to support Recovery Housing</li> </ol>

# Existing Work to Address the Drivers of Rising Deaths

Here are examples of recent Community and State activities most focused on addressing rising overdose deaths:

Pillar	Projects
Treatment	<ol style="list-style-type: none"> <li>1. MAT: No waiting lists, strong methadone infrastructure, and MAT at the Adult Correctional Institutions</li> <li>2. 24 hours buprenorphine induction hotline</li> <li>3. BH Link's services</li> <li>4. Coordination between DCYF and social workers at birthing hospitals, to support pregnant moms</li> <li>5. Telemedicine started quickly when COVID began, through work of providers, insurers, and the state – and is continuing through Executive Order</li> </ol>
Overall	<ol style="list-style-type: none"> <li>1. Being a small state and having the ability to connect, network, and share resources across the state. Examples include the Task Force and CODE meetings</li> <li>2. Strong support of the recovery community from state's top administrative and legislative leaders</li> <li>3. Starting to talk about race equity in a serious way, including with the creation of the Overdose Task Force Race Equity Workgroup</li> <li>4. More community engagement – listening to community voices</li> <li>5. More state interagency coordination and collaboration</li> <li>6. More data collection – and sharing data between the state and community organizations more quickly</li> </ol>

## Report Recommendations

# Report Recommendations

Recommendations are tied to pillars. We have color coded recommendations related to key themes from the quantitative and qualitative findings – the effects of the rise of **Fentanyl**, **COVID**, and **Structural Racism**.

We have gleaned a range of recommendations from the stakeholder outreach, which are reflected throughout this report.

We begin with a list of **Short-Term Recommendations**, which can be implemented quickly, to address the rising number of overdose deaths. Then, we summarize a set of **Priority Recommendations** by pillar and highlighting those most likely to stem the rising tide of overdose deaths, based on the growing fentanyl presence in our drug supply and the negative impact of COVID-19 on Rhode Islanders who use drugs.

Then, we share the **entire list of Recommendations** that the team has created from stakeholder input

Finally, we will be sharing a **full report** of the data and the focus group and interviews later by early January.

# Suggested Priority Recommendations

## (A) Fight Fentanyl Overdoses with Expanded Harm Reduction

1. Address the challenges of the **Good Samaritan Law**: Formally evaluate the Good Samaritan law to determine its implementation, and support proposed changes that arise from that evaluation
2. Review the feasibility (including impacts of federal law and potential need for legislative action) of a **pilot overdose prevention site** that would provide a broad range of drug user health services
3. Establish a workplan to ensure every strategy and implementation plan has **actions steps to reduce structural racism**, and that these actions are measured and reviewed routinely
4. Add “**Harm Reduction**” specifically to the Rescue Pillar title

## (B, C) Address COVID Impact: Recovery Resiliency/Capital/ Connections

1. Prioritize and fund a **medication-first treatment** approach that reduces barriers to continued engagement with treatment, including residential treatment
2. Include and fund **trauma-informed mental health services** in SUD or alcohol treatment
3. Recruit and support peers who **reflect the diversity** of those they serve
4. Elevate focused **employment and re-employment** efforts (including Real Pathways & Recovery Friendly Workplaces), with work that is more conducive to recovery
5. Safely prioritize **in-person recovery services** wherever possible

## (D) Create a Focused, Staffed Governance Structure

1. Elevate the community's voice, including appointing **community co-chairs** to co-lead each workgroup
2. Create a full time, dedicated **Director of Overdose Prevention + Response**, who leads an **interagency team** with project management capacity, to address the full recommendations
3. Create a **standing legislative/policy team** with membership from each of the Workgroups, advisory to the Task Force
4. **Overhaul state messaging**: fact-based; nationally researched, locally tailored for variety of audiences: people who use drugs, their families and supporters, and people not using drugs.
5. Align and braid dollars and pursue new funding, to **ensure sustainable support for key efforts to prevent overdose deaths**

# Short-Term Recommendations

Here are a set of short-term recommendations from the research, with longer-term proposals below:

Activity	Pillar
Secure Project Management and functional lead staff from existing state staff. Carry out an audit of all existing meetings/stakeholder engagements to coordinate current work.	Governance
Continue more effective messaging development for harm reduction, especially focused on men 50-59 years old, using SOR dollars	Harm Reduction
Seek dollars for basic needs for people who use drugs, as existing funding cannot purchase many harm reduction items (needles, fentanyl strips, etc.)	Harm Reduction
Work with the Department of Labor & Training to create messaging promoting harm reduction, treatment, and recovery support	Harm Reduction/all
Fully implement the 10,000 Chances Program, and get naloxone into public housing	Harm Reduction
Designate a facilitator for an ongoing conversation with community and law enforcement leaders to enable harm reduction practices and by building champions for harm reduction in law enforcement.	Harm Reduction
Recruit and train more Peer Recovery Specialists who speak languages other than English, who are people of color, and who are recently in recovery	Recovery
Ensure more face-to-face recovery services that take into account COVID restrictions	Recovery
Strategize on hand-offs from treatment, especially for those with anxiety and prior behavioral diagnoses, and those in the demographics most affected by fatal overdoses	Treatment
Implement more effective data sharing between Peer Recovery Specialists and people in treatment, with better sharing of consent	Treatment
Maximize access to treatment: Allow health homes to serve the same people without co-payment challenges, stop tox screens before treatment access	Treatment
Engaging the judiciary system to promote treatment and recovery	Treatment/Recovery

# Final Thoughts

---

## Thank you!

**The Task Force co-chairs** – Director Power and Dr. Alexander-Scott, plus Assistant Secretary Ana Novais and Dr. Jim McDonald

**Our research team** – Sarah St. Laurent, Deb Florio, Charlotte Kreger, and Cathie Cool Rumsey for the daily work and organization

Plus the **interagency team** that contributed greatly: Linda Mahoney, James Rajotte, Annice Correia Gabel

**Our data and analytics advisory team**

And the 150+ people who gave hours of their time to speak with us and teach us about their experience. It was a gift.

- ❑ Please share your feedback and reactions with us, the co-chairs, or workgroup leads:

[Marti.Rosenberg@ohhs.ri.gov](mailto:Marti.Rosenberg@ohhs.ri.gov)

[Kimberly.Paull@ohhs.ri.gov](mailto:Kimberly.Paull@ohhs.ri.gov)

- ❑ We will develop and share a final summary of this work in a narrative document in January 2021.
- ❑ The co-chairs will ask the workgroups to take the next steps towards further vetting and implementation of these recommendations.

## Discussion – Questions and Answers



## Full Recommendations, by Pillar and Cross-Pillar

# Key Components of the Priority Recommendations

## (A) Fight Fentanyl Overdoses with Expanded Harm Reduction

**Why?** We heard in our focus groups that more people are dying from fentanyl – it's everywhere and increasingly lethal.

Harm reduction acknowledges that banning a behavior only drives it underground. People will find ways to use drugs - how do make safe options as easy to access as possible?

## (B, C) Address COVID Impact: Recovery Resiliency/Capital/ Connections

**Why?** Recovery is fragile for anyone, at any time - but fentanyl, COVID anxiety and isolation, discrimination and disparities, as well as institutional mistrust are devastating to those finding their way.

In 2020, people – men especially – were more likely to die at home before rescue arrived, which may be driven by fentanyl lethality, using alone, and/or fear of calling for services. Though the majority were not in treatment, many did show patterns of recovery or reduced use.

Strengthening recovery resilience, especially for high-risk groups, means that each person, and their community, will sail a stronger ship through the next storms.

## (D) Create a Focused, Staffed Governance Structure

**Why?** Rhode Island is blessed with committed, innovative and respective leaders, advocates, and experts.

However, we lack a central structure to ensure these ideas are fully vetted, staffed and carried forward, funding is focused, and the overall response reflects the diversity of voices served.

# Proposed Recommendations – Harm Reduction & Rescue

1. **Harm Reduction:** Naloxone has been our main focus of rescue. We must move beyond naloxone, to include harm reduction

F

SR

A. **Rename** the Task Force's Rescue Pillar to Harm Reduction & Rescue to recognize the importance of Harm Reduction in the Task Force's work

F

SR

4A

B. Maximize access to recognized **harm reduction materials**. Includes culturally competent distribution of, awareness of and ability to test for fentanyl in illicit drugs through messaging and distribution of fentanyl test strips, plus resources for needle exchange and other materials.

F

C

2,4

C. Facilitate the planning for a pilot **overdose prevention site**

F

SR

D. Rebuild community trust of law enforcement by **designating a facilitator for a conversation with community and law enforcement leaders** to enable harm reduction practices and by building champions for harm reduction in law enforcement

F

C

SR

1C

E. Establish a workplan to ensure every strategy and implementation plan has **actions steps to reduce structural racism**, and that these actions are measured and reviewed routinely.

SR

2. **Address the challenges of the Good Samaritan Law:** Carry out a formal evaluation of the Good Samaritan law to determine how it is implemented and support effective implementation; initiate trainings and the law and its reach; pursue legislation as needed.

F

C

3. Pursue additional data-sharing between RIDOH and community organizations, to allow for more effective community outreach

# Full Recommendations – Recovery

F C SR All

**1. Expand Recovery beyond “absence of drug use”** - include reduced use and other Harm Reduction activities, and a focus on ending social isolation, especially during COVID.

**2. Recovery Capital:** Focus on purpose, place, and people as anchors, especially countering the impact of COVID:

F C SR 2C

A. Purpose: Expand and promote Recovery-Friendly Workplaces and employment and career ladder support for those with SUD and COVID job displacement. Support educational pathways as well for people in recovery.

F C SR 1,2

B, Place: As noted in Prevention, make significant investments in housing resources, such as Recovery Housing and other step-down facilities, especially for people shown to be at highest risk (people 50-59 years of age, people of color, veterans)

F C SR 3

C. People: Promote safe in-person support to counter social isolation and deepen recovery community networks, which COVID has eroded

F C SR

**3. Certified Peer Recovery Specialists:** Broaden support and investment in the peer recovery network, with increased payment for, and recruitment and training of a more diverse pool of peer recovery specialists to better represent people in new recovery. Turn Peer Recovery Specialists into a career ladder position.

# Full Recommendations – Governance (Cross-Pillar)

The following governance recommendations are meant to enable our collective response to achieve the previous recommendations with speed, agility, and equity.

1. To achieve a more formally **coordinated and effective statewide structure** to prevent overdoses and pursue a healthier Rhode Island

A. Appoint **community co-chairs** to co-lead the task force workgroups

B, Create a full time, dedicated **Director of Overdose Prevention + Response** to lead the administration's Task Force activities and to be responsible for aligning the public/private shared work

C. The Director of Overdose Response leads an **interagency team** that breaks down silos between individual state agencies, builds connections with community partners as it implements the Task Force Strategic Plan, and highlights the needs for better data about the overdose response

D. Interagency team will include a **robust project management structure**, to support the Task Force Workgroups and track and report on Strategic Plan action items in a public dashboard. Ensure that adequate data are collected, and that data and evaluations are shared.

2. The Task Force Co-Chairs should pursue more **adequate and diverse community representation**, with community voices encouraged to participate in Workgroups, and more BIPOC members added to the Task Force itself

3. To add shared policy work to Rhode Island's addiction response, create a **standing legislative/policy team** with membership from each of the Workgroups, to create an annual legislative agenda - for example, in FY21 to support the upcoming Governor's Housing Bonds

# Full Recommendations – Messaging (Cross-Pillar)

- F** **C** **SR** **D** **Prevention:** Overhaul state messaging efforts, by looking toward nationally researched and locally tailored messaging that is proven to reach a variety of audiences: people who use drugs, their families and supporters, and people not using drugs.
- F** **C** **SR** **3** **Harm Reduction:** Emphasize anti-stigma messaging, by looking toward nationally researched and locally tailored messaging that is proven to reach a variety of audiences: people who use drugs, their families and supporters, and people not using drugs.
- F** **C** **SR** **3** **Recovery** messaging must include the shift from addiction as a vice to addiction as a disease; the hope of a full life; and the reinforcement that true recovery is personal, self-directed, and doesn't look the same – but always needs a welcoming community.

# Full Recommendations – Treatment

## 1. Access to medically adequate sustained treatment by lowering barriers and opening doors:

- C SR 2 A. Medication First MAT access – a low-threshold MAT system - including no prior authorizations, no need for tox screen if not medically required, allowances for missed appointments. Explore uptake of non-opioid MAT options for alcohol-use disorder and for stimulants where possible.
- C SR 2 B. Ensure access to adequate, quality, residential treatment: pursue mandate of minimum 30-day residential treatment, when medically-necessary, with no reauthorizations necessary until Day 31; implement sufficient family SUD residential treatment facility; no concurrent review.
- C SR C. Carry out rate review activities, to support rates that allow (a) behavioral health workforce to become more diverse and culturally competent.(b) adequately compensate for existing services, and for (c) medication first and reduced administrative barriers

## 2. Enhance Content of Substance Use Treatment to Reinforce Connection to Harm Reduction, Prevention, Recovery

- F SR 2 A. Strengths-based treatment that nudges people towards trusting their providers and encouraging return [i.e. providing clean needles, fentanyl strips etc.]
- C SR 3 B. Ensure that SUD treatment includes integrated mental health services - and working with OHIC, does so without additional co-pays
- C SR C. Primary Care Providers should partner with SUD providers just as any other specialty – eReferrals, CCD integration, expectation of provider coordination for each shared patient.

# Full Recommendations – Treatment

## 3. Ensure Consistent, High Quality Services among a range of delivery models

c

A. Facilitate patient consent to data sharing and support provider workflow changes to ensure person-focused, successful care and allow communication between treatment facilities and community case navigators.

c

SR

2

B. Evaluate the Centers of Excellence model, to determine their effectiveness and ensure quality, and compare to a Nurse Care Manager model

c

SR

C. Promote safe and accessible patient complaint functions and clarify the state's actions to respond to complaints



# Full Recommendations - Prevention

## 1. Promote Prevention Efforts That Build Personal and Community Resilience, Alternatives to Substance Use, Targeted Messaging

F C SR 3

A. Invest in mental-health and community resiliency: **Trauma-informed behavioral health services** across the lifespan, with a focus on addressing ACEs, toxic stress, family and community violence-reduction programs

F C SR 3

B. Pursue policies around social determinants or social experiences that help **reduce desires to turn to drug use**. Also, pursue prevention policies that safeguard against social isolation (i.e. against cyber bullying, or to promote grief supports)

F C 4A

C. Invest in proven **prevention educational programs**, including updated facts about the crisis i.e. significant rise of fentanyl), the existence of harm reduction strategies (Narcan and fentanyl test strips), and strategies for mental health resilience

F 1D

D. Prevention programs should be **across the lifespan**, with focus on youth (high school and middle school) as well as older adults, including seniors who may be at risk of casual opioid, benzodiazepine, or alcohol misuse

F C SR 1


E. Prioritize prevention strategies that **recognize race equity, eliminate structural racism and disparities** based on race, ethnicity, sexual orientation, gender, gender identity, age, and ability

## Appendix 1: Additional Quantitative Data

# Quantitative Analysis: Age groups

“2020”: Fatal Overdose between Dec. 2019 – June 2020

“2019”: Fatal Overdose between Dec. 2018 – June 2019



# Died at residence vs elsewhere

Total population	2019	2020
Vitals	181	223
Medicaid	108	129
Medicaid % of Total	60%	58%

We analyzed the differences between 2019 and 2020 cohorts on those who died at their residence vs who died elsewhere.

People who died in their residence in were less likely to be on Medicaid, more likely to be married, less likely to have tobacco contribute to death.

Those who died in other places were more likely to have tobacco contribute to death and have a previous OUD diagnosis (and less likely to have an AUD diagnosis).

	2019	2020	% change 2019 to 2020
Died at Residence - Male	55	83	51%
Died at Residence - Female	25	26	4%
<b>Died at Residence - Total</b>	<b>80</b>	<b>109</b>	<b>36%</b>
All Overdoses - Male	127	164	29%
All Overdoses - Female	54	59	9%
<b>All Overdoses</b>	<b>181</b>	<b>223</b>	<b>23%</b>

	2019	2020	Difference	Difference %
<b>Total Died at other than Residence</b>	101	114	13	12.87%

Died at Residence											
Factor	2019	2020	2019 - %	2020 - %	Difference %	Source	Standard Error	Upper CI	Lower CI	Z	p
Marital Status : Married	6	23	7.50%	21.10%	13.60%	Vitals_Deaths	0.05	23.19%	4.01%	2.78	0.00
Tobacco as a cause : No	47	51	58.75%	46.79%	-11.96%	Vitals_Deaths	0.07	2.33%	-26.25%	-1.64	0.05
Any Medicaid Claim	50	55	62.50%	50.46%	-12.04%	Medicaid Claims	0.07	2.12%	-26.21%	-1.67	0.05

Died Elsewhere											
Factor	2019	2020	2019 - %	2020 - %	Difference %	Source	Standard Error	Upper CI	Lower CI	Z	p
Tobacco as a cause : Yes	8	20	7.92%	17.54%	9.62%	Vitals_Deaths	0.04	18.37%	0.88%	2.16	0.02
Prior Alcohol Use Disorder	32	30	55.17%	40.54%	-14.63%	Medicaid Claims	0.09	2.37%	-31.63%	-1.69	0.05
Prior Opioid Use Disorder	28	46	48.28%	62.16%	13.89%	Medicaid Claims	0.09	30.84%	-3.07%	1.61	0.05

# 2020 Cohort Comparison: Died at residence vs elsewhere

Total population	2019	2020
Vitals	181	223
Medicaid	108	129
Medicaid % of Total	60%	58%

In 2020, those who died in residence were less likely to have prior Medicaid claims, more likely to be aged 40-49, and less likely to have prior OUD dx

## Comparison of 2020 cohort between those who died at other places vs those who died at residence

Factor	2020 Other places	2020 Residence	2020 Other places %	2020 Residence %	Difference %	Source	Standard Error	Upper CI	Lower CI	Z	p
Age 20-29	21	9	18.4%	8.3%	-10.2%	Vitals_Deaths	0.045	-1.4%	-19.0%	-2.265	0.012
Age 40-49	20	34	17.5%	31.2%	13.6%	Vitals_Deaths	0.057	24.8%	2.5%	2.399	0.008
Age 50-59	34	23	29.8%	21.1%	-8.7%	Vitals_Deaths	0.058	2.6%	-20.1%	-1.504	0.066
Marital Status : Married	15	23	13.2%	21.1%	7.9%	Vitals_Deaths	0.050	17.8%	-1.9%	1.579	0.057
Tobacco as a cause : Yes	20	10	17.5%	9.2%	-8.4%	Vitals_Deaths	0.045	0.5%	-17.2%	-1.856	0.032
Any Medicaid Claim	74	55	64.9%	50.5%	-14.5%	Medicaid Claims	0.066	-1.6%	-27.3%	-2.206	0.014
Prior Claim of Substance Use Disorder other than AUD	56	34	75.7%	61.8%	-13.9%	Medicaid Claims	0.082	2.3%	-30.0%	-1.683	0.046
Prior claim of Substance Use Disorder other than OUD	58	37	78.4%	67.3%	-11.1%	Medicaid Claims	0.079	4.4%	-26.7%	-1.400	0.081
Prior Opioid Use Disorder	46	22	62.16%	40.00%	-22.16%	Medicaid Claims	0.086845	-5.14%	-39.18%	-2.55	0.01
Prior Overdose	17	4	22.97%	7.27%	-15.70%	Medicaid Claims	0.060145	-3.91%	-27.49%	-2.61	0.00


# Fentanyl, isolation, and institutional mistrust means many more people in 2020 died in residence – especially men.

Population	2019	2020	% change
Died in Residence	80	109	36%
All deaths	181	223	24%
% of Total	44%	49%	

There were 51% more men – versus 4% more women – who died in their residence in the 2020 cohort. This compares to a 23% increase in all overdoses – 29% for men, 9% for women – in the two cohorts.

Note that the 51% increase, though large, was not statistically significant ( $p = 0.13$ ) Statistically significant ( $P < 0.05$ ) differences from 2019 to 2020

Percent Change in Fatal Overdoses by Location of Death and Gender, 2019 to 2020



Those who died in their residence in 2020 were more likely to:

- ✓ Be married (21% of total, up from 7.5% in 2019)
- ✓ Not use tobacco (47% of total, down from 59%)
- ✓ Not be in Medicaid (50% of total, down from 63% in 2019)

Those who died elsewhere in 2020 were more likely to:

- ✓ Have a prior OUD claim (62% of total, up from 48% of total)
- ✓ Not have a prior Alcohol Use Disorder claims (40% of total, down from 55%)

# Methadone Deaths and Enrollment in Treatment

- We analyzed the deaths dataset and Medicaid claims dataset to determine the enrollment percentage in MAT within 3 months of death date.
- There were 51 people, in total, who died of Methadone as one of the causes. Of these 51 people, 38 (74.5%) of them were in Medicaid . Of those, 24 people were in Treatment within 3 months of death.

	2019	2020	Grand Total
<b>Number of People</b>	<b>19</b>	<b>32</b>	<b>51</b>

	2019	2020	Total	2019%	2020%
Enrolled in MAT within 3 months of Death	6	18	24	50.0%	69.2%
NOT Enrolled in MAT within 3 months of Death	6	8	14	50.0%	30.8%
<b>Grand Total</b>	<b>12</b>	<b>26</b>	<b>38</b>		

The table shows the frequency count of co-occurrence of Methadone with other codes as causes of Death

Month Of Death	2019	2020	Total
Jan	2	4	6
Feb	3	4	7
Mar	2	5	7
Apr	2	6	8
May	5	8	13
Jun	1	3	4
Dec	4	2	6
<b>Grand Total</b>	<b>19</b>	<b>32</b>	<b>51</b>


Code	Description	Frequency
T404	Synthetic Opioids Other than Methadone (Fentanyl etc)	27
X44	Drug Poisoning	7
T402	Opioid Overdose	5
X42	Drug Poisoning	5
T424	BENZODIAZEPINE	5
F191	Pyschoactive Substance Abuse	4
T509	Unspecified drugs, medicaments and biological substances	4
F109	Alcohol	3
I517	Cardiomegaly	3
K746	Biliary cirrhosis unspecified	3
T405	Cocaine	3
F179	Nicotine	2
I119	Hypertensive heart disease without heart failure	2
J449	Chronic obstructive pulmonary disease unspecified	2
J459	Severe persistent asthma with status asthmaticus	2
T401	Heroin	2

# Methadone Deaths and Cause lines

Based on ICD codes in both 2019 and 2020, there were 51 deaths with methadone as one of the causes. Of these 51, there were 38 (74.5%) whose cause lines had “Methadone”. Of these 38, 37 of them are in “Cause Line A”, indicating “primary” causes of death.

methadone	37	heroin	2	intoxicatio	1
		diphenhydramine	2	intox	1
intoxication	25	benzodiazepin	1	ethanol	1
acute	17	bupr	1	complicat	1
fentanyl	16	lexapro	1	tramad	1
cocaine	9	fluoxetine	1	gabapentin	1
combined	8	diazepam	1	venlafaxin	1
alcohol	3	olanazpine	1	buprenorphine	1
alprazolam	2	etizolam	1	intoxi	1
anpp	2	probable	1	xanax	1
		benzodiazepine	1	mdma	1
morphine	2	ivanpp	1	fentynal	1
with	2	tramadol	1	ketamine	1
acetyl	1	comigned	1	drug	1

Of the 37 people, 13 (7.2% of 2019 cohort) of them were in 2019 and 24 (10.8% of 2020 cohort) were in 2020.



## Cause Line A

ACUTE METHADONE AND LEXAPRO INTOXICATION COMPLICAT
ACUTE METHADONE AND GABAPENTIN INTOXICATION
COMBINED FENTANYL;HEROIN AND METHADONE INTOXICATIO
ACUTE METHADONE AND ETIZOLAM INTOXICATION
ACUTE COCAINE METHADONE AND DIPHENHYDRAMINE INTOXI
ACUTE 3;4;MDMA;KETAMINE;AND METHADONE INTOXICATION
ACUTE FENTANYL AND METHADONE INTOXICATION
METHADONE INTOXICATION
METHADONE INTOXICATION
COMIGNED DRUG;COCAINE;HEROIN;METHADONE;FENTANYL AN
ACUTE METHADONE AND ALPRAZOLAM INTOXICATION
METHADONE INTOXICATION
ACUTE ALCOHOL;METHADONE;DIPHENHYDRAMINE;VENLAFAXIN
COMBINED COCAINE;METHADONE;BENZODIAZEPINE AND BUPR
ACUTE COCAINE AND METHADONE INTOXICATION
METHADONE INTOXICATION
COMBINED FENTANYL;METHADONE;TRAMADOL AND DIAZEPAM
COMBINED FENTANYL;MORPHINE;METHADONE;BENZODIAZEPIN
ACUTE METHADONE AND ETHANOL INTOXICATION
ACUTE FENTANYL;4 ANPP;METHADONE;COCAINE AND TRAMAD
FENTANYL AND METHADONE INTOXICATION
METHADONE INTOXICATION
ACUTE FENTANYL;4 ANPP AND METHADONE INTOXICATION
COMBINED FENTANYL; COCAINE; METHADONE INTOXICATION
METHADONE;FLUOXETINE;OLANAZPINE;BUPRENORPHINE AND
ACUTE COCAINE;FENTANYL AND METHADONE INTOXICATION
PROBABLE METHADONE INTOXICATION
METHADONE INTOXICATION
ACUTE METHADONE AND XANAX INTOXICATION
METHADONE INTOXICATION
ACUTE COCAINE FENTANYL METHADONE AND ALPRAZOLAM IN
COMBINED FENTANYL IVANPP; METHADONE AND ALCOHOL IN
COMBINED FENTANYL AND METHADONE INTOXICATION WITH
FENTANYL MORPHINE AND METHADONE INTOXICATION



# DLT – Wages Analysis: Reference


2020 cohort: More people with wages in recent quarters, but overall, those wages are lower

Q1								
YEAR	count ( $\geq$ \$0)	mean	25th perc	median	75th perc	min	max	stdev
2019	45	\$7,308	\$2,612	\$5,077	\$10,911	\$0	\$24,955	\$6,076
2020	68	\$6,267	\$1,614	\$3,840	\$8,205	\$36	\$62,841	\$8,555
Q2								
YEAR	count ( $\geq$ \$0)	mean	25th perc	median	75th perc	min	max	stdev
2019	47	\$6,343	\$1,384	\$4,585	\$9,619	\$20	\$22,661	\$5,950
2020	72	\$8,158	\$1,437	\$3,702	\$7,990	\$0	\$203,869	\$23,761
Q3								
YEAR	count ( $\geq$ \$0)	mean	25th perc	median	75th perc	min	max	stdev
2019	43	\$6,895	\$1,887	\$4,260	\$9,987	\$80	\$24,139	\$6,561
2020	66	\$6,165	\$939	\$3,197	\$9,316	\$0	\$52,000	\$8,132
Q4								
YEAR	count ( $\geq$ \$0)	mean	25th perc	median	75th perc	min	max	stdev
2019	43	\$6,965	\$1,996	\$5,410	\$9,487	\$178	\$32,229	\$6,631
2020	65	\$9,887	\$1,452	\$4,328	\$9,518	\$0	\$252,000	\$30,814
Q1 to Q4								
YEAR	count ( $\geq$ \$0)	mean	25th perc	median	75th perc	min	max	stdev
2019	60	\$20,383	\$3,798	\$12,334	\$30,169	\$143	\$90,679	\$22,258
2020	85	\$24,271	\$4,016	\$10,112	\$26,116	\$30	\$570,710	\$62,594


# DLT – Wages Analysis

2020 cohort: More people with wages in recent quarters, but overall, those wages are lower

**Four Quarters (Total) Prior to Death:**  
% Wages by FPL Wage Bands, 2019 vs 2020 OD Deaths



**1 Quarter Prior to Quarter Death:**  
% Wages by FPL Wage Bands, 2019 vs 2020 OD Deaths




# Roger Williams: Impact of MAT Facility Closure

- For comparison, we identified individuals who received MAT at other (non-Roger Williams) facilities for the same time period as the RW-MAT Cohort, 4/1/19 to 5/31/19 (NRW-MAT Cohort)
- Higher mortality among RW-MAT Cohort 12-months post-closure, but 0 deaths 6-months post closure
  - **Urge caution in interpretation due to relatively low numbers for RW-MAT Cohort**

Mortality Rate for RW-MAT Cohort vs NRW-MAT Cohort		
	RW-MAT Cohort	NRW-MAT Cohort
Count	96	1,519
6-month deaths (%)	0 (0%)	7 (0.46%)
12-month deaths (%)	3 (3.13%)	21 (1.38%)

# Admissions Minus Releases, by Year / Month

Total minus Total by Year and Month



## Appendix 2: Additional Qualitative Findings

# What we learned – Harm Reduction & Rescue

Harm reduction means putting health and wellbeing first, working with people to mitigate the negative health impacts of drug use, further reducing the chance that drug use will lead to death and other adverse health outcomes

## Main Observations from Focus Groups & Interviews

- **Drug Supply:** The rise of fentanyl potency, volume, and variety (including analogues, and fentanyl found in many non-opioids) is key to understanding Harm Reduction & Rescue. We must educate people about the risk – especially those who use do not use opioids (or use casually).
- **Data:** Inability for more real-time data sharing between the state and community organizations creates barriers for fully effective harm reduction outreach and community engagement.
- **Harm Reduction Strategies:**
  - Rhode Island has focused significantly on distributing naloxone. This is a critical strategy and must continue – but we must go beyond naloxone to prioritize additional harm reduction activities.
  - Stakeholders throughout the state support planning for a pilot in-person overdose prevention site, that could also distribute naloxone, clean needles, treatment and recovery information.
  - There are significant challenges in the relationships between law enforcement and people who use drugs – and sometimes, with the organizations that serve them. This affects all people who use drugs but is exacerbated for people of color.
  - For example, the Good Samaritan Law is not working as it should to encourage people to call for help. The research team heard examples of law enforcement members not understanding the law – and other times when people at an overdose scene are arrested for bench warrants despite the existence of the law. Stakeholders noted that this prevents people from feeling safe to call 911 for an overdose.
- **Messaging:** Stakeholders identified that the state is not the correct messenger about harm reduction, and they also want an ongoing in-depth discussion about the most effective messaging and messengers for the range of rescue efforts.

# What we learned – Recovery

Recovery is a process of change through which individuals improve their health and wellness, live a self-directed life, and strive to reach their full potential. Certified Peer Recovery Specialists are a main focus of the state’s recovery strategy

## Main Observations from Focus Groups & Interviews

Our major recovery strategy has been to promote and support peer recovery specialists, and we have not had an adequate back-up system for the impact of fentanyl and COVID. Also, this strategy did not always work for people of color who did not have peers who reflected their background. We must shore up the scaffolding for recovery capital beyond just peers.

- **Defining Recovery:** Stakeholders have identified new ways of defining and measuring Recovery (success) rather than just avoidance of drug use, including for people who are not opioid users but who are seeking recovery and people who are opioid users but who are choosing not to use MAR/MAT, many times because they have tried it and don't like it. For example, success might be people who engage with a harm reduction organization and begin to try and use less, or use more safely,
- **Recovery Capital:** The rise of COVID uncovered the weaknesses of recovery capital for people in Rhode Island at most risk: people in shorter-term recovery, people of color, and people who were most isolated.
- **Peer Recovery Specialists:** While peers are a critical resource, there are holes in the peer network, in terms of diversity and cultural competency of existing peers and funding options for them.

# What we learned – Governance

A well-structured statewide response allows us to respond thoughtfully and quickly to new ground information, and in coordinated motion with clear signals from state and community leadership.

## Main Observations from Focus Groups & Interviews

- **Silos:** Avoidable silos in state agencies and community organizations keep us from being as coordinated as we need to be in addressing the opioid epidemic
- **Stakeholder Engagement:**
  - Stakeholders appreciate being involved in discussions about the crisis, but are concerned that the discussions do not routinely lead to firm action
  - Decision-makers do not routinely include community members or people affected by the issue – and appear mostly white, middle-class
- **Coordinated Management:** We lack central project management, finance, and evaluation functions, especially for grant-funded projects. For example, some Task Force Workgroups are not staffed and do not have a recognized escalation path



# What we learned – Treatment

Medication Assisted Treatment (MAT) is where our focus lies, but residential treatment and detox serve critical roles as well.

## Main Observations from Focus Groups & Interviews

Rhode Island does get a lot right with our treatment services. For people with insurance, there is good access for MAT, and we see people making the strides they want to make. (Access is not possible for those without insurance, however – which includes many people who are undocumented.)

The key to examining Treatment is to focus on Access, Content, and Quality, and to recognize that we must target treatment for poly-substances, not just opioids.

- **Low barrier access to sustained treatment on demand is critical:** There are no waiting lists for MAT, but stakeholders noted that procedural barriers – not capacity – prevent initial and continuous access, in contrast to other states (MA, VT). We also heard that residential treatment lasts 14-30 days at most, which is routinely acknowledged as too short – and people must often get reapproved every 3 days, which can disturb treatment. Access is worse for women, especially women with children who need residential treatment. And after residential treatment, there are often not enough beds in step-down facilities, like Recovery Housing. There are data-sharing barriers in place that do not allow community organizations to communicate with patients in treatment facilities. And overall, COVID has made access to all in-person services more difficult.
- **Treatment Focus:** Substance Use Disorder (SUD) treatment rarely includes integrated mental health services, although stakeholders affirmed that SUD is almost always co-occurring with mental health needs, which have been exacerbated during COVID. MAT in the primary care and medical setting must be in addition to the behavioral health therapies required for treatment success.
- **Quality:** There are different levels of quality through the system. Stakeholders identified a lack of an effective, responsive feedback function to discuss treatment that doesn't line up to expectations and needs. And we must make our workforce more diverse and culturally competent.

# What we learned - Prevention

**Prevention:** Reduce the number of people who develop addiction, including but not limited to opioids, or encounter problematic use of substances.

## Main Observations from Focus Groups & Interviews

Stakeholders agree that we must look far upstream for true prevention: stopping and treating trauma and violence, ensuring social determinants of health (especially housing), and ending discrimination and disparities. We need to use and systematically advocate for prevention strategies that have been proven to work and invest heavily in them – for both people who do not use drugs and for those in recovery.

- **Expand Determinants of Prevention:** The key to prevention is similar to what it takes to build recovery capital: social determinants of health, including purpose (such as a job with adequate income), place (safe housing), addressing structural racism, and trauma-informed physical and behavioral healthcare treatment
- **Prevent Initial *and* Recurring Symptoms of Disease:** Recovery is another form of prevention, and vice versa. Align select Recovery and Prevention strategies to ensure messages, funding, and investments reinforce the continuum. Rhode Island needs more investment in addiction prevention in general.
- **Target messaging:** As with Harm Reduction, stakeholders are concerned that our current messaging does not share critical facts, may not have the right messengers, and misses people across populations who use or may use drugs – and those who do not identify as people who use drugs. They want an ongoing in-depth discussion about the most effective messaging and messengers for prevention, with a focus on culturally and linguistically sensitive language.

End of Presentation



# PUBLIC COMMENT